Ingenious e-Brain Solutions will host webinar on “PCSK9 in Cardiovascular Disease” followed by a Q&A session on the following dates. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor is causing a major upheaval in pharmaceutical sector especially Amgen’s Evolocumab and Sanofi & Regeneron Alirocumab. The initial trials demonstrated superior levels never seen before and making it as the hot new drug target to treat cardiovascular disease.

This webinar will provide an overview of PCSK9 in cardiovascular disease by presenting details of patents, products, white spaces, key companies, key research institutes and trend analysis around this technology. This webinar will also provide inventors and investors with the resources to navigate through this period of exponential growth and opportunity in cardiovascular therapy further exploring the approaches for collaboration and best practices in IP industry.



Select the date of your interest:

USA:  July 26, 2016 at 2:00 pm EDT August 02, 2016 at 2:00 pm EDT August 09, 2016 at 2:00 pm EDT

Europe: July 28, 2016 at 11:00 am CET August 04, 2016 at 11:00 am CET August 11, 2016 at 11:00 am CET

Declaration- This is a secured message and your details will remain confidential.